Inhibition of MAP4K4 through RNAi
RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the strands may be modified (e.g., one or both ends of the sense strand is modified by 2′-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, the antisense strand may also be modified by a 2′-O-methyl group at the penultimate 5′-end nucleotide to greatly reduce off-target silencing.
1. A blunt-ended double-stranded RNA (dsRNA) for inhibiting expression of a MAP4K4 gene, comprising:
(1) a sense strand of at least 25 nucleotides in length, having a 5′-end and a 3′-end, wherein the sense strand is modified with 2′OMe-modified ribose sugars, comprising a continuous stretch of 2′OMe-modified ribose sugars on the 5′-end, a continuous stretch of 2′OMe-modified ribose sugars on the 3′-end, and a central region that is unmodified, and,
an antisense strand of at least 25 nucleotides in length having a 5′-end and a 3′-end, which hybridizes to the sense strand,
wherein the sense strand comprises a sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 12, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 50, 53, 54, and 56,
wherein the antisense strand comprises a sequence selected from the group consisting of: SEQ ID NO: 2, 4, 6, 8, 10, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, and 52,
wherein the dsRNA does not form a hairpin, and
wherein the dsRNA is capable of inhibiting expression of a MAP4K4 gene.
2. The dsRNA of claim 1 , wherein the dsRNA comprises a modification of a base, and/or a phosphodiester linkage.
3. The dsRNA of claim 1 , wherein the dsRNA comprises a hydrophobic modification of one or more bases.
4. The dsRNA of claim 1 , wherein the sense strand of the dsRNA comprises 12-14 and 10-12 consecutive 2′OMe-modified ribose sugars at the 5′-end of the sense strand and the 3′-end of the sense strand, respectively.
5. A composition comprising the dsRNA of claim 1 , and a pharmaceutically acceptable carrier or diluent.
6. A method for inhibiting the expression of a MAP4K4 gene in a mammalian cell, comprising contacting the mammalian cell with the dsRNA of claim 1 .
7. A method of treating a patient for a disease characterized by overexpression of a MAP4K4 gene, comprising administering to the patient a dsRNA of claim 1 , wherein the dsRNA mediates guide sequence-dependent reduction in MAP4K4 expression.
8. The dsRNA of claim 1 , wherein the sense strand comprises SEQ ID NO:19.
9. The dsRNA of claim 1 , wherein the sense strand comprises SEQ ID NO:50.